Ticiana A. Leal, MD

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss frontline therapy approaches in HER2-mutant non–small cell lung cancer and the evolving role of chemoimmunotherapy.

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss the importance of biomarker testing in non–small cell lung cancer and tools for detecting HER2-mutant disease.

Panelists discuss the role of ctDNA (liquid biopsy) in clinical practice, highlighting its benefits and limitations in detecting actionable mutations, interpreting results, and guiding treatment decisions when tissue testing is insufficient.

Panelists discuss strategies for identifying and managing ROS1-positive NSCLC, focusing on comprehensive testing approaches, emerging clinical data, and factors that guide treatment decisions.

Experts explore biomarkers, sequencing, and access strategies for extensive-stage small cell lung cancer maintenance, spotlighting tarlatamab, ADC combos, and clinical trials.

Relapsed small cell lung cancer care evolves as tarlatamab boosts survival but needs CRS/ICANS monitoring, while lurbinectedin offers simpler dosing.

Experts weigh maintenance options after chemo-immunotherapy in extensive-stage SCLC, navigating brain mets, cytopenias, and real-world care barriers.

Experts weigh brain metastases limits in IMFORTA and share real-world tips for maintenance lurbinectedin plus atezolizumab.

Experts weigh IMfortis data, side effects, and patient selection as lurbinectedin-atezolizumab maintenance reshapes extensive-stage SCLC care.

IMforté data show larotrectinib plus atezolizumab maintenance extends PFS and OS in extensive-stage small cell lung cancer—real-world considerations.

Experts unpack IMfortis data on intensifying atezolizumab maintenance after induction chemoimmunotherapy in extensive-stage small cell lung cancer.

Ticiana Leal, MD, discusses clinical considerations surrounding the diagnosis of LEMS in patients with lung cancer.

Experts discuss the persistent challenges in EGFR-mutated non–small cell lung cancer , including central nervous system (CNS) progression and treatment sequencing, emphasizing the urgent need for more transformative strategies beyond current combination regimens, greater inclusion of complex patient populations in trials, and the critical role of comprehensive biomarker testing and shared decision-making in delivering personalized, future-forward care.

Experts discuss the expanding treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting emerging strategies beyond tyrosine kinase inhibitors (TKIs)—including novel immunotherapy combinations and antibody-drug conjugates (ADCs)—with particular interest in bispecific antibodies and TROP2-directed ADCs that may offer new options for patients progressing on targeted therapy, despite ongoing challenges in translating immune-based approaches into consistent survival gains.

Experts discussed how, despite several new third-generation EGFR tyrosine kinase inhibitors (TKIs) in development, the real progress in treating EGFR-mutant lung cancer is likely to come from combination therapies rather than new monotherapies, emphasizing the need for treatments that deliver meaningful improvements over current standards rather than just incremental changes.

Resistance management in EGFR-mutant lung cancer relies on both liquid and tissue biopsies to guide therapy, with careful interpretation of molecular findings and multidisciplinary collaboration essential to balancing precision medicine advances against patient safety and evidence-based care.

Panelists discuss how the next 3 to 5 years will likely see T-cell engagers moving into earlier treatment lines, potential ADCs replacing chemotherapy in first-line therapy, and the critical need for better biomarker testing to optimize treatment sequencing and patient selection in an increasingly complex therapeutic landscape.

Panelists discuss novel and investigational therapies under study for small cell lung cancer, including immunotherapy combinations and targeted approaches.

Panelists discuss real-world experiences with novel agents for relapsed small cell lung cancer, focusing on efficacy, safety, and patient selection.

Panelists discuss treatment decision-making in second-line small cell lung cancer, balancing efficacy, toxicity, and patient-specific factors.

Panelists discuss the importance of shared decision-making, patient communication, and adherence strategies in small cell lung cancer treatment.

Panelists discuss therapeutic strategies for recurrent small cell lung cancer with central nervous system involvement, emphasizing adverse event (AE) management and patient support.

Panelists discuss the clinical relevance of emerging trial data evaluating combination maintenance strategies and their potential role in practice.

Panelists discuss practical considerations in selecting first-line regimens and managing maintenance therapy in patients responding to initial treatment.

Panelists review key clinical trial data demonstrating the efficacy and safety of chemo-immunotherapy regimens in extensive-stage small cell lung cancer.

Panelists discuss the diagnostic evaluation and staging process for extensive-stage small cell lung cancer, emphasizing comprehensive imaging and laboratory workup to guide initial treatment planning.

Panelists discuss how patient and disease factors, such as performance status, comorbidities, and extent of metastases, influence first-line treatment selection in small cell lung cancer.

Experts shared that while amivantamab combined with chemotherapy in MARIPOSA- 2 can cause challenging toxicities, careful dose adjustments, premedication, and vigilant monitoring help manage adverse effects and support continued treatment.

Experts highlight evolving evidence that continuing EGFR tyrosine kinase inhibitors (TKIs) with chemotherapy after progression may improve outcomes, but emphasize that treatment sequencing decisions must be personalized based on emerging data, patient factors, and drug availability.

Panelists discuss how emerging therapies including DLL3-targeted ADCs, trispecific T-cell engagers, CAR T cells, and radioligand therapies represent promising approaches that may offer single-dose treatments or enhanced efficacy, though more data on durability and optimal sequencing are needed.